We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Japanese Researchers Demonstrate Novel Transcutaneous Influenza Vaccination Using a Dissolving Microneedle Patch

By LabMedica International staff writers
Posted on 27 Jul 2015
Vaccination via a biodegradable microneedle patch was shown to generate immune response to various strains of the influenza virus that were equal to or stronger than those induced by traditional hypodermic needle injection.

Previous attempts using microneedles made of silicon or metal were not successful primarily due to the risk of the needles breaking off in the skin, leaving tiny fragments behind. More...
To avoid this problem, investigators at Osaka University (Japan) prepared microneedle patches from hyaluronic acid, a naturally occurring and water soluble biological material. The "MicroHyala" microneedle patch was loaded with the material to be injected and then applied like a plaster. The needles pierced the top layer of skin and then dissolved into the body, taking the vaccine with them.

In the current study the investigators examined the clinical safety and efficacy of the MicroHyala vaccination method using MH (flu-MH), which contains trivalent influenza hemagglutinins (15 micrograms each). Subjects were treated transcutaneously (TCI group) with a flu-MH microneedle patch, and were compared with subjects who received subcutaneous injections (SCI group) of a solution containing 15 micrograms of each influenza antigen.

Results published in the July 2015 issue of the journal Biomaterials revealed that no severe local or systemic adverse events were detected in either group. Immune responses against A/H1N1 and A/H3N2 strains were induced equally in the TCI and SCI groups. Moreover, the efficacy of the vaccine against the B strain in the TCI group was stronger than that in the SCI group.

"Our novel transcutaneous vaccination using a dissolving microneedle patch is the only application vaccination system that is readily adaptable for widespread practical use," said senior author Dr. Shinsaku Nakagawa, professor of medical pharmacy at Osaka University. "Because the new patch is so easy to use, we believe it will be particularly effective in supporting vaccination in developing countries."

"We were excited to see that our new microneedle patch is just as effective as the needle-delivered flu vaccines, and in some cases even more effective," said Dr. Nakagawa. "We have shown that the patch is safe and that it works well. Since it is also painless and very easy for non-trained people to use, we think it could bring about a major change in the way we administer vaccines globally."

Related Links:

Osaka University



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: A family of molecules could help diagnose and treat breast cancer (Photo courtesy of Shutterstock)

Molecular Biomarkers Pave Way for New Tests to Diagnose and Predict Breast Cancer

Despite playing essential roles in tissue development and immune protection, the contribution of proteoglycans in cancer remains poorly understood. Some proteoglycans appear to shield the body from cancer,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.